Sofinnova Investments related stories
All articles and analysis
Lumira invests in First Aid Shot Therapy's $24 mln Series C roundU.S.-based consumer healthcare company First Aid Shot Therapy (FAST) has closed a US$24 million Series C financing. Johnson & Johnson Innovation-JJDC led the round and was joined by new investor Lumira Capital, a Canadian venture capital firm. Sofinnova Ventures, Redmile Group, HealthQuest Capital and other existing investors also participated. FAST, which provides over-the-counter medicine in liquid shot form, said the funding will be used to expand its product portfolio and support growth of its customer base. With the round's close, Lumira Managing General Partner Peter van der Velden has joined the company's board of directors.
First Aid Shot Therapy rakes in $24 mln Series CBurlingame, California-based First Aid Shot Therapy, a developer of over-the-counter medicine in liquid shot form, has raised $24 million in Series C funding. Johnson & Johnson Innovation – JJDC Inc led the round with participation from other investors that included Lumira Capital, Sofinnova Ventures, Redmile Group and HealthQuest Capital.
- VC-backed Aclaris goes public
Malvern, Pennsylvania-based Aclaris Therapeutics, a dermatology-focused specialty pharmaceutical company, has raised $55 million for its IPO after pricing its 5 million shares at $11 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol "ACRS." Jefferies LLC and Citigroup Global Markets Inc are serving as the lead underwriters. Aclaris is backed by Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures
- VC-backed Mirna Therapeutics debuts IPO
Austin, Texas-based Mirna Therapeutics Inc, a biopharmaceutical company focused on developing cancer-treating drugs, has raised almost $44 million for its IPO after pricing its 6.25 million shares at $7 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol "MIRN." Citigroup and Leerink Partners are the lead underwriters. Mirna's backers included Sofinnova Ventures, New Enterprise Associates, Pfizer Ventures, Osage University Partners and Correlation Ventures.
Venture rethinks biotechMarket volatility hasn’t dampened investor enthusiasm or chased away crossovers, but company creation is slow
- James joins Thoma Bravo
Jennifer James has joined Thoma Bravo LLC as Director, Head of Investor Relations & Marketing. James most recently served as Partner, Investor Relations & Marketing, for Sofinnova Ventures.
Three young funds off to fast starts--VCJ fund performance reportRecent vintage GGV, Union Square, Sofinnova funds power ahead at Oregon PERF.
Fund performance: Three young funds off to fast startsRecent vintage GGV, Union Square, Sofinnova funds power ahead
IPO Aftermarket: Life sciences keep dominating as Pure Storage files its IPOThrough the end of July, VCJ reports that 50 VC-backed companies have gone public on the NYSE or Nasdaq exchanges